About
Chen Schor has served as Adicet Bio's President and Chief Executive Officer and as a director since the September 2020 merger of resTORbio and Former Adicet. He co-founded resTORbio in 2016 and served as its director, President and CEO until the merger.
Earlier in his career he was President, CEO and director of Synta Pharmaceuticals through its 2017 merger with Madrigal Pharmaceuticals, and previously the company's EVP and COO. He also led Novalere FP as President and CEO and served as Chief Business Officer of Eleven Biotherapeutics and VP of Business Development for global branded products at Teva Pharmaceutical Industries. He holds an MBA from Tel Aviv University, a B.A. in Economics and Accounting from Haifa University and a B.A. in Biology from Tel Aviv University.
Roles
Adicet Bio, Inc.
President, Chief Executive Officer & Director · Current role
2020–present
resTORbio, Inc.
Co-founder, director, President & CEO · Co-founded the company and led it until the September 2020 merger that formed Adicet Bio.
2016-2020
Synta Pharmaceuticals Corp.
President, CEO & director · Served until the company's July 2017 merger with Madrigal Pharmaceuticals; previously EVP and Chief Operating Officer from 2014 to 2016.
2015-2017
Novalere FP, Inc.
President & CEO
2012-2014
Eleven Biotherapeutics, Inc.
Chief Business Officer
2011-2012
Teva Pharmaceutical Industries Limited
VP, Business Development, global branded products
2009-2011
External Roles
Karyopharm Therapeutics Inc.
Board member
—
Carbon Biosciences, Inc.
Chair of the board
—
Alliance for Cancer Gene Therapy
Board member (non-profit)
—
Fixed Compensation
FY 2025
All other compensation
$22,782
Performance Compensation
Data from FY 2025
Cash incentive
Non-equity incentive plan compensation
$284,592
Stock awards
Option awards (grant-date fair value)
$512,079